SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-23-038030
Filing Date
2023-11-09
Accepted
2023-11-09 07:04:55
Documents
14
Period of Report
2023-11-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K avtx-20231109.htm   iXBRL 8-K 26768
2 EX-99.1 ex-9913q23earningsrelease.htm EX-99.1 107355
6 GRAPHIC avalo-logoxblk1.jpg GRAPHIC 99614
  Complete submission text file 0001628280-23-038030.txt   405919

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT avtx-20231109.xsd EX-101.SCH 1969
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT avtx-20231109_lab.xml EX-101.LAB 23182
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT avtx-20231109_pre.xml EX-101.PRE 12041
8 EXTRACTED XBRL INSTANCE DOCUMENT avtx-20231109_htm.xml XML 2625
Mailing Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850
Business Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850 410-522-8707
Avalo Therapeutics, Inc. (Filer) CIK: 0001534120 (see all company filings)

IRS No.: 450705648 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37590 | Film No.: 231390005
SIC: 2834 Pharmaceutical Preparations